Adverum Biotechnologies Newsroom

Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation

TipRanksMay 16 04:39 ET

Adverum Biotechnologies Is Maintained at Buy by Truist Securities

Adverum Biotechnologies Is Maintained at Buy by Truist Securities

Dow JonesMay 15 14:32 ET

Express News | Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target

BenzingaMay 15 14:21 ET

Adverum Biotechnologies (ADVM) Receives a Buy From Truist Financial

TipRanksMay 15 07:27 ET

Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress

Yahoo FinanceMay 10 15:36 ET

Express News | HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

BenzingaMay 10 08:32 ET

Express News | Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate

BenzingaMay 9 17:21 ET

Express News | Adverum Biotechnologies Inc: $193.3 Mln in Cash, Cash Equivalents and Short-Term Investments Expected to Fund Operations Into Late 2025

ReutersMay 9 16:44 ET

Adverum Biotechnologies | 10-Q: Quarterly report

Futu NewsMay 9 16:21 ET · Announcements

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations

GlobeNewswireMay 9 16:05 ET

Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM

Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM

Dow JonesMay 9 16:05 ET

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular

GlobeNewswireMay 3 08:00 ET

Adverum Biotechnologies a New Buy at H.C. Wainwright on Wet AMD Gene Therapy

Seeking AlphaMay 1 13:18 ET

Adverum Biotechnologies Price Target Announced at $30.00/Share by HC Wainwright & Co.

Adverum Biotechnologies Price Target Announced at $30.00/Share by HC Wainwright & Co.

Dow JonesApr 30 06:18 ET

Express News | Adverum Biotechnologies, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

ReutersApr 30 06:02 ET

Express News | Adverum Biotechnologies Inc : Mizuho Cuts Target Price to $22 From $40

ReutersApr 29 06:39 ET

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the compan

BenzingaApr 25 16:40 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS

BenzingaApr 23 16:31 ET

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Yahoo FinanceApr 23 09:40 ET

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Yahoo FinanceApr 4 09:40 ET